Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–64.
Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58.
Caballero MT, Polack FP. Respiratory syncytial virus is an “opportunistic” killer. Pediatr Pulmonol. 2018;53:664–7.
Srikantiah P, Vora P, Klugman KP. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Clin Infect Dis. 2021;73:S177–9.
Mazur NI, Löwensteyn YN, Willemsen JE, et al. Global respiratory syncytial virus-related infant community deaths. Clin Infect Dis. 2021;73:S229–37.
Caballero MT, Bianchi AM, Grigaites SD, et al. Community mortality due to respiratory syncytial virus in argentina: population-based surveillance study. Clin Infect Dis. 2021;73:S210–7.
Gill CJ, Mwananyanda L, MacLeod WB, et al. Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. Lancet Glob Health. 2022;10:e269–77.
Simões EAF, Dani V, Potdar V, et al. Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: a prospective community cohort study in rural Maharashtra. India Clinical Infectious Diseases. 2021;73:S193-202.
Zhang S, Akmar LZ, Bailey F, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680–7.
Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med. 2017;195:96–103.
Group* TIm-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998;102:531–7.
COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady MT, Byington CL, et al. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2014;134:415–20.
Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2:e367–74.
Commissioner O of the. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. FDA. 2023; published online July 18. (Accessed 15 Aug 2023).
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022;386:837–46.
U.S. FDA Approves ABRYSVOTM, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32–36 Weeks of Gestational Age. (Accessed 23 Aug 2023).
Dvorkin J, De Luca J, Alvarez-Paggi D, Caballero MT. Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies. Infect Drug Resist. 2023;16:595–605.
Wittenauer R, Pecenka C, Baral R. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective. BMC Med. 2023;21:121.
Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires. Argentina BMC Infect Dis. 2015;15:447.
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327–37.
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–71.
Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Methodological considerations for cost of illness studies of enteric fever. Clin Infect Dis. 2020;71:S111–9.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
Rubinstein A, Zerbino MC, Cejas C, López A. Making Universal Health Care Effective in Argentina: a blueprint for reform. Health Syst Reform. 2018;4:203–13.
Macinko J, Montenegro H, Nebot Adell C, Etienne C. Grupo de Trabajo de Atención Primaria de Salud de la Organización Panamericana de la Salud [Renewing primary health care in the Americas]. Rev Panam Salud Publica. 2007;21:73–84.
Tipo de cobertura de salud de la población (en porcentaje). (Accessed 22 Aug 2022).
Madhi SA, Polack FP, Piedra PA, et al. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020; published online July 29 https://doi.org/10.1056/NEJMoa1908380.
Atwell JE, Geoghegan S, Karron RA, Polack FP. Clinical predictors of critical lower respiratory tract illness due to respiratory syncytial virus in infants and children: data to inform case definitions for efficacy trials. J Infect Dis. 2016;214:1712–6.
Recommendations for the use of oxygen in COVID 19 patients. 2021. Ministry of Health, Argentina. https://bancos.salud.gob.ar/sites/default/files/2021-05/Recomendaciones_para_el_uso_de_oxigeno_en_pacientes_COVID%2019.pdf. .
Griffiths, U.; Rheingans, R.; Walker, D. Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the impact of rotavirus diarrhoea. World Health Organization, Geneva, Switzerland. 2005. (Accessed 12 May 2017).
Ferolla FM, Hijano DR, Acosta PL, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187:983–90.
Caballero MT, Bianchi AM, Nuño A, et al. Mortality associated with acute respiratory infections among children at home. J Infect Dis. 2019;219:358–64.
Instituto Nacional de Estadística y Censos (INDEC), Analía Calero, Georgina Giglio. Valorización mensual de la canasta básica alimentaria y de la canasta básica total. Gran Buenos Aires. Informes técnicos. Condiciones de Vida. 2022;7(7), published online Dec. https://www.indec.gob.ar/uploads/informesdeprensa/canasta_01_23DF5760FF57.pdf.
Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. Jornal de Pediatria. 2017;93:75–83.
Lucion MF, Juarez MD, Viegas M, et al. Virus respiratorio sincicial: Patrón clínico epidemiológico en niños internados en un hospital pediátrico durante los años 2000–2013. Arch Argent Pediatr. 2014;112:397–404.
Marcone DN, Durand LO, Azziz-Baumgartner E, et al. Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina. BMC Infect Dis. 2015;15:447.
Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol. 2020;48:56–61.
Moyes J, Tempia S, Walaza S, et al. The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016. BMC Med. 2023;21:146.
Baral R, Mambule I, Vodicka E, et al. Estimating the economic impact of respiratory syncytial virus and other acute respiratory infections among infants receiving care at a referral Hospital in Malawi. J Pediatr Infect Dis Soc. 2020;9:738–45.
Bhuiyan MU, Luby SP, Alamgir NI, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7:010412.
Limeres Manuel, De la Puente. ANÁLISIS DEL COMPORTAMIENTO DEL MERCADO DE MEDICAMENTOS Y POSICIONAMIENTO DEL PROGRAMA REMEDIAR. Informe final. Programa de Fortalecimiento de la Estrategia de Atención Primaria de la Salud Programa REMEDIAR ÁREA de Monitoreo y Evaluación. 2013; published online Oct. http://186.33.221.24/medicamentos//files/Analisis_del_Comportamiento_del_Mercado_de_Medicamentos.pdf.
Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21:123–31.
WDI – The World by Income and Region. (Accessed 17 Mar 2023).
Instituto Nacional de Estadística y Censos (INDEC). Valorización mensual de la canasta básica alimentaria y de la canasta básica total. Gran Buenos Aires, Argentina. Condiciones de vida. 2022;6(8); published online May. https://www.indec.gob.ar/uploads/informesdeprensa/canasta_06_226144AF5583.pdf.
Buendía JA, Patino DG, Sinisterra D. Cost of illness of RSV infection in a middle-income tropical country. Turk J Pediatr. 2021;63:673–82.
